FULCRUM THERAPEUTICS INC (FULC) Stock Price, Quote, News and Overview
NASDAQ:FULC - Nasdaq - US3596161097 - Common Stock - Currency: USD
FULC Quote, Performance and Key Statistics
3.85
0 (0%)
The current stock price of FULC is 3.85 USD. In the past month the price decreased by -7%. In the past year, price decreased by -59.9%.
FULC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.62 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About FULC
Company Profile
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 76 full-time employees. The company went IPO on 2019-07-18. The firm is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The firm has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.
Company Info
FULCRUM THERAPEUTICS INC
26 Landsdowne Street
Cambridge MASSACHUSETTS 02139 US
CEO: Robert J. Gould
Employees: 76
Company Website: https://www.fulcrumtx.com/
Investor Relations: https://ir.fulcrumtx.com/
Phone: 16176518851
FULCRUM THERAPEUTICS INC / FULC FAQ
What is the stock price of FULCRUM THERAPEUTICS INC today?
The current stock price of FULC is 3.85 USD.
What is the ticker symbol for FULCRUM THERAPEUTICS INC stock?
The exchange symbol of FULCRUM THERAPEUTICS INC is FULC and it is listed on the Nasdaq exchange.
On which exchange is FULC stock listed?
FULC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for FULCRUM THERAPEUTICS INC stock?
13 analysts have analysed FULC and the average price target is 5.78 USD. This implies a price increase of 50.13% is expected in the next year compared to the current price of 3.85. Check the FULCRUM THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is FULCRUM THERAPEUTICS INC worth?
FULCRUM THERAPEUTICS INC (FULC) has a market capitalization of 207.67M USD. This makes FULC a Micro Cap stock.
How many employees does FULCRUM THERAPEUTICS INC have?
FULCRUM THERAPEUTICS INC (FULC) currently has 76 employees.
What are the support and resistance levels for FULCRUM THERAPEUTICS INC (FULC) stock?
FULCRUM THERAPEUTICS INC (FULC) has a support level at 3.7 and a resistance level at 4.16. Check the full technical report for a detailed analysis of FULC support and resistance levels.
Is FULCRUM THERAPEUTICS INC (FULC) expected to grow?
The Revenue of FULCRUM THERAPEUTICS INC (FULC) is expected to grow by 3367.74% in the next year. Check the estimates tab for more information on the FULC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy FULCRUM THERAPEUTICS INC (FULC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FULC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FULC, evaluating the profitability, health, valuation and growth aspects
- FULCRUM THERAPEUTICS INC (FULC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- FULCRUM THERAPEUTICS INC (FULC) Sales and EPS estimates to see what analysts future expectations are.
- FULCRUM THERAPEUTICS INC (FULC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- FULCRUM THERAPEUTICS INC (FULC) Insider and Institutional Ownership to learn about the owners and their transactions.
- FULCRUM THERAPEUTICS INC (FULC) Stock Chart to make your own analysis
- FULCRUM THERAPEUTICS INC (FULC) Latest news and press-releases to stay up to date.
Does FULCRUM THERAPEUTICS INC (FULC) stock pay dividends?
FULC does not pay a dividend.
When does FULCRUM THERAPEUTICS INC (FULC) report earnings?
FULCRUM THERAPEUTICS INC (FULC) will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of FULCRUM THERAPEUTICS INC (FULC)?
FULCRUM THERAPEUTICS INC (FULC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.31).
What is the Short Interest ratio of FULCRUM THERAPEUTICS INC (FULC) stock?
The outstanding short interest for FULCRUM THERAPEUTICS INC (FULC) is 8.19% of its float. Check the ownership tab for more information on the FULC short interest.
FULC Technical Analysis
FULC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FULC. While FULC has a great health rating, there are worries on its profitability.
FULC Financial Highlights
Over the last trailing twelve months FULC reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS increased by 81.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -6.42% | ||
| ROE | -6.96% | ||
| Debt/Equity | 0 |
FULC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 74% to FULC. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 85.47% and a revenue growth 3367.74% for FULC